Clinical Trial Update: A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases [Phase 1, Phase 2]

View source ↗

Summary

SCTC21C is being studied for plasma cell–driven autoimmune diseases, including IgA nephropathy, in Phase 1/2 trials that are not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• SCTC21C

Snippet

Sponsor: Sinocelltech Ltd. | Conditions: IgA Nephropathy | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING